Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Feb 2012

Spindler Karen-Lise Garm, Pallisgaard Niels, Vogelius Ivan, Jakobsen Anders

Abstract excerpt

PURPOSE: The present study investigated the levels of circulating cell-free DNA (cfDNA) in plasma from patients with metastatic colorectal cancer (mCRC) in relation to third-line treatment with cetuximab and irinotecan and the quantitative relationship of cfDNA with tumor-specific mutations in plasma. EXPERIMENTAL DESIGN: Inclusion criteria were histopathologically verified chemotherapy-resistant mCRC, adequate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Camptothecin

Share to Cetuximab

Share to Irinotecan

Share to Neoplasm Metastasis

Share to ras Proteins

Source

Identifiers

PMID: 22228631
DOI: 10.1158/1078-0432.CCR-11-0564

Genes

KRAS
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.PMID 22228631Read ↗

Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy.Semantic proximity Read ↗

Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer.Semantic proximity Read ↗

Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.Semantic proximity Read ↗

The Clinical Impact of Quantitative Cell-free DNA, KRAS, and BRAF Mutations on Response to Anti-EGFR Treatment in Patients with Metastatic Colorectal Cancer.Semantic proximity Read ↗

Comparison of KRAS Mutation Assessment in Tumor DNA and Circulating Free DNA in Plasma and Serum SamplesSemantic proximity Read ↗

RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancerSemantic proximity Read ↗

KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer.Semantic proximity Read ↗

Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC.Semantic proximity Read ↗

Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer.Semantic proximity Read ↗

Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study.Semantic proximity Read ↗

Evaluation of KRAS, NRAS and BRAF mutations detection in plasma using an automated system for patients with metastatic colorectal cancer.Semantic proximity Read ↗

Detection of tumor-derived cell-free DNA from colorectal cancer peritoneal metastases in plasma and peritoneal fluid.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.